Anti-inflammatory effects of aspirin and sodium salicylate

European Journal of Pharmacology

Volumn 447, Issue 1, 2002, Pages 1-9

  Amann, Rainer ^a   Peskar, Bernhard A ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cyclooxygenase; Non steroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ARACHIDONIC ACID; CALCIMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLIBENCLAMIDE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LIPOXIN; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTANOID; PROTEIN P50; SALICYLATE SODIUM; THROMBOXANE A2; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; BIOSYNTHESIS; CARDIOVASCULAR SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH PROTECTION; ULCEROGENESIS; ANIMAL; DIGESTIVE SYSTEM; DRUG INTERACTION; HUMAN; SIGNAL TRANSDUCTION;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ASPIRIN; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; GASTROINTESTINAL SYSTEM; HUMAN; SIGNAL TRANSDUCTION; SODIUM SALICYLATE; SUPPORT, NON-U.S. GOV'T; ANIMALS; DIGESTIVE SYSTEM; HUMANS;

EID: 0037188750     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01828-9     Document Type: Review

References (106)

1. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger
2. Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity
3. Sodium salicylate enhances the expression of cyclooxygenase-2 in endotoxin-stimulated human mononuclear cells
4. Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages
5. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation
6. Biodistribution of salicylates: A clue to the understanding of some effects and side effects
7. Biodistribution of mild analgesics
8. Salicylate may prevent the inhibitory effect of indomethacin on serum thromboxane formation in man
9. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
10. Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclooxygenase: Evidence from "in vivo" drug interaction studies in rats
11. Identification of a soluble salicylic acid-binding protein that may function in signal transduction in the plant disease-resistance response
12. Induction, modification, and transduction of the salicylic acid signal in plant defense responses
13. Antiinflammatory action of salicylates: Aspirin is not a prodrug for salicylate against rat carrageenin pleurisy
14. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation
15. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions
16. Salicylates, nitric oxide, malaria, and Reye's syndrome
17. Prevention of reoxygenation injury by sodium salicylate in isolated-perfused rat liver
18. Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: Adenosine dependent and independent mechanisms
19. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB
20. Sodium salicylate interferes with the inhibitory effects of aspirin and indomethacin on human platelets
21. P38 mitogen activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes
22. Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition
23. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases
24. Aspirin enhances myocardial inducible nitric oxide synthase activity in guinea pigs
25. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
26. Antagonism of the gastrointestinal ulcerogenic effect of some non-steroidal anti-inflammatory agents by sodium salicylate
27. Gastrointestinal cytoprotection by indomethacin+sodium salicylate combination in rat
28. Role of interferon regulatory factor-1 and mitogen-activated protein kinase pathways in the induction of nitric oxide synthase-2 in retinal pigmented epithelial cells
29. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid
30. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
31. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogues
32. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs
33. Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo
34. Anomalous biological effects of salicylates and prostaglandins
35. Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue
36. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach
37. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation
38. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells
39. Both p38 alpha (MAPK) and JNK/SAPK pathways are important for induction of nitric-oxide synthase by interleukin-1 beta in rat glomerular mesangial cells
40. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
41. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
42. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
43. Prostaglandin synthase 2
44. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity
45. Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages
46. Cyclooxygenase inhibition as a strategy to ameliorate brain injury
47. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout
48. One hundred years of aspirin
49. Levels of cylclooxygenase-1 and -2 mRNA expression at various stages of acute gastric injury induced by ischemia-reperfusion in rats
50. Nitric oxide and salicylic acid signaling in plant defense
51. Inhibition of NF-kappa B by sodium salicylate and aspirin
52. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
53. Benzoic acid 2-hydroxylase, a soluble oxygenase from tobacco, catalyzes salicylic acid biosynthesis
54. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity
55. Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs
56. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach
57. Lipoxins: Revelations on resolution
58. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells
59. Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation
60. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
61. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: Role of arachidonic acid
62. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin
63. Clinical pharmacokinetics of the salicylates
64. Aspirin and salicylate enhances the induction of inducible nitric oxide synthase in cultured rat smooth muscle cells
65. COX-2 and Alzheimer's disease: Potential roles in inflammation and neurodegeneration
66. Lipopolysaccharide-induced expression of prostaglandin H synthase-2 in alveolar macrophages is inhibited by dexamethasone but not by aspirin
67. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways
68. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
69. Effects of non-steroidal anti-inflammatory drugs on rat gastric mucosal leukotriene C4 and prostanoid release: Relation to ethanol-induced injury
70. Interaction of cyclooxygenase-2 inhibitors and salicylate in gastric mucosal damage
71. Role of ATP-sensitive potassium channels in prostaglandin-mediated gastroprotection in the rat
72. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration
73. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis
74. The cellular association of sodium salicylate and indomethacin in peritoneal fluid of ascites bearing mice
75. Bio-distribution in rats of some salicylates with low gastric ulcerogenicity
76. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin
77. Gastric cytoprotection by sodium salicylate
78. Atherosclerosis - An inflammatory disease
79. Aspirin, platelets and thrombosis: Theory and practice
80. Acetylation of prostaglandin synthase by aspirin
81. Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts
82. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation
83. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation
84. Lipoxins and novel aspirin-triggered 15-epi-lipoxins [ATL]: A jungle of cell-cell interactions or a therapeutic opportunity?
85. Effects of aspirin-like drugs on nitric oxide synthesis in rat vascular smooth muscle cells
86. Prostaglandins and aspirin: An alternative view
87. Prostaglandin endoperoxide H synthases-1 and -2
88. Prostaglandins and the anti-inflammatory activities of aspirin and sodium salicylate
89. Aus der Taube'schen Klinik. Über die Resultate der Behandlung der Polyarthritis rheumatica mit Salicylsäure
90. Cyclooxygenase-independent actions of cyclooxygenase inhibitors
91. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues
92. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress
93. Aspirin-like drugs, ethanol-induced rat gastric injury and mucosal eicosanoid release
94. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
95. Salicylate in the perfusate during ischemia/reperfusion prevented mitochondrial injury
96. Salicylic acid fails to inhibit generation of thromboxane A2 activity in platelets after in vivo administration to the rat
97. The inhibition of cyclooxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines
98. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
99. Arachidonate metabolic pathways in cells harvested from rat pleural cavity at various times after carrageenan administration
100. Is local biotransformation the key to understanding the pharmacological activity of salicylates and gold drugs?
101. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
102. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells
103. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
104. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate
105. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
106. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta